


Product Introduction

Oprozomib (ONX 0912)

Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of **20S proteasome** β 5/LMP7 with **IC50** of 36 nM/82 nM.

Technical Data:

Molecular Weight (MW):	532.61	
Formula:	C ₂₅ H ₃₂ N ₄ O ₇ S	
Solubility (25°C)	DMSO 107 mg/mL	
* <1 mg/ml means slightly soluble or insoluble:	Water <1 mg/mL	
	Ethanol <1 mg/mL	
Purity:	>98%	
Storage:	3 years -20°C Powder	
	6 months-80°C in DMSO	
CAS No.:	935888-69-0	

Biological Activity

The anti-MM activity of Oprozomib is associated with activation of caspase-8, caspase-9, caspase-3, and PARP, as well as inhibition of migration of MM cells and angiogenesis. [2]

Oprozomib is demonstrated an absolute bioavailability of up to 39% in rodents and dogs. It is well tolerated with repeated oral administration at doses resulting in >80% proteasome inhibition in most tissues and elicited an antitumor response in multiple human tumor xenograft and mouse syngeneic models [1].

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

References

- [1] Zhou HJ, et al. J Med Chem, 2009, 52(9), 3028-3038.
- [2] Chauhan D, et al. Blood, 2010, 116(23), 4906-4915.
- [3] Muchamuel T, Nat Med, 2009, 15(7), 781-787.



Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. This item is only for R&D purpose not for commercial business in kilos. Buyers should overview the patent issue in their countries.